GYRE THERAPEUTICS, INC. (GYRE): Nasdaq/NYSE listing notice — Catalyst Biosciences receives Nasdaq delisting notice for minimum bid price non-compliance

GYRE THERAPEUTICS, INC.

Received Nasdaq notice on Nov 2, 2022; stock closed below $1.00 for 30 consecutive trading days.
Company has 180 calendar days, until May 1, 2023, to regain compliance with Minimum Bid Price Requirement.
If bid price closes at or above $1.00 for 10 consecutive days before deadline, compliance achieved.
If not cured, Nasdaq may grant a second 180-day grace period if Company meets other listing standards.
Failure to cure could lead to delisting; Company may appeal to a Nasdaq hearings panel.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.82

GYRE THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

November 2, 2022, Catalyst Biosciences, Inc., a Delaware Corporation (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) informing the Company that because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company is not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Marketplace Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Marke

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

GYRE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-22-040002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.